Lilly Acquires Diabetes Candidates In Deal With Transition Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
After ending its efforts to develop inhaled insulin, Lilly rebuilds in-house pipeline of diabetes candidates.